Considering Subsequent Treatment in NDMM After Teclistamab-Based Induction
Marc S. Raab, MD, PhD, details how agents like carfilzomib may play a role in treatment after progression on teclistamab-based induction therapy.
Universal Testing May Help Bolster Long Term Ovarian Cancer Survivorship
Genetic testing information can be used to risk-stratify ovarian cancer survivors for breast cancer, particularly those with BRCA1 or BRCA2 mutations.
Determining Fitness Is Key in Mantle Cell Lymphoma Treatment Selection
Patients with mantle cell lymphoma who are older and have less fitness may be eligible for regimens that include bendamustine/rituximab.
IMNN-001/Chemo Displays TME Shift in Newly Diagnosed Ovarian Cancer
IMNN-001 exhibits prolonged favorable safety among patients with advanced newly diagnosed ovarian cancer.
Developing a Patient-Centric Approach in Small Cell Lung Cancer Care
Employing patient-reported outcomes may help include those with small cell lung cancer in the shared decision-making process.
Optimizing the Timing of Genetic Testing in Advanced Ovarian Cancer
Genetic testing for ovarian cancer may help inform treatment decisions for patients with advanced disease, particularly regarding PARP inhibitor use.
Giredestrant Combo Significantly Boosts PFS in ER+ Advanced Breast Cancer
Data from the phase 3 evERA trial show a trend toward improved overall survival with giredestrant plus everolimus in this breast cancer population.
Dara-KRd Regimen Displays Prolonged PFS in Newly Diagnosed Multiple Myeloma
The median PFS was not reached with daratumumab-lenalidomide maintenance after a median follow-up of 49 months in those with multiple myeloma.
Mitazalimab/Chemo Yields Promising Survival/Responses in Untreated PDAC
At 30 months, mitazalimab plus mFOLFIRINOX achieved an OS rate of 21% in patients with previously untreated metastatic PDAC.
How To Discuss Death? A Conversation of Mortality in Cancer Care
Daniel C. McFarland, DO, and guest William S. Breitbart, MD, discuss the critical role of meaning-centered therapy in addressing the psychosocial needs of patients with cancer.
Understanding and Managing Disease Heterogeneity in Small Cell Lung Cancer
In the SWOG S2409 PRISM trial, over 800 patients with small cell lung cancer will receive different treatment regimens based on their disease subtype.
Belantamab Exhibits Rapid/Prolonged Plasmablast Cell Reduction in Myeloma
No TRAEs leading to dose discontinuation, DLTs, or belantamab-related corneal events above grade 1 occurred with belantamab in multiple myeloma.
MRD Negativity Improves With Daratumumab Maintenance Combo in NDMM
Updated findings from AURIGA support the value of adding subcutaneous daratumumab to lenalidomide maintenance in MRD-positive NDMM after transplant.
Managing AEs with Gemcitabine Intravesical System in NMIBC
Gary Steinberg, MD, compared the AE profile of the gemcitabine intravesical system for BCG-unresponsive NMIBC with other intravesical therapies.
Sonrotoclax Combo Shows Safety, Promising Efficacy in R/R Multiple Myeloma
Phase 1b/2 BGB-11417-105 trial data showed low rates of high-grade infection and hematologic toxicity with sonrotoclax-based therapy in multiple myeloma.
P53 Mutations May Reveal Viability of Different Pancreatic Cancer Therapies
Patients with PDAC and non-GOF mutations had less favorable OS and DFS outcomes in various instances compared with those who had wild-type or GOF mutations.
Belantamab Mafodotin Triplet Highlights Low Ocular Toxicity in Intermediate-Fit, Frail Newly Diagnosed Myeloma
Belantamab mafodotin plus lenalidomide and dexamethasone yielded a stringent CR of 42.9% in patients with newly diagnosed multiple myeloma.
Daratumumab Quadruplet Improves Efficacy in Transplant-Ineligible or-Deferred, Newly Diagnosed Myeloma
Daratumumab, lenalidomide, ixazomib, and dexamethasone yielded PFS/OS outcomes in transplant-ineligible, newly diagnosed myeloma.
CHMP Recommends Expanded Approval for 2 Pembrolizumab Indications
The agency has recommended approval for subcutaneous pembrolizumab in all previous solid tumor indications, and for pembrolizumab in recurrent HNSCC.
Toripalimab Consolidation Improves Survival in Limited-Stage SCLC
In patients with LS-SCLC who were ineligible for a prophylactic cranial irradiation, toripalimab appeared to decrease the progression of brain metastases.
Concurrent CAR T Product Infusion Appears Feasible in R/R Multiple Myeloma
Data from the TANDEMM trial show enduring responses with concurrent anti-GPRC5D and anti-BCMA therapy in relapsed/refractory multiple myeloma.
FDA Approves SC Pembrolizumab Formulation in Solid Tumors
Data from the phase 3 3475A-D77 trial support the FDA approval of subcutaneous pembrolizumab across different pediatric and adult solid tumor indications.
Advancing AI in Oncology: Critical Considerations for Clinical Practice
Greater regulatory and policy clarity may better optimize clinician use of artificial intelligence in treating patients with cancer.
Eque-Cel Displays Favorable Long-Term Survival in R/R Multiple Myeloma
The long-term safety profile of equecabtagene autoleucel was manageable, with no new safety signals identified in those with multiple myeloma.
Arlo-Cel Yields Efficacy, Safety in Previously Treated R/R Multiple Myeloma
As a 1-time dose, arlo-cel yielded promising efficacy and safety for patients with previously treated relapsed/refractory multiple myeloma.
Psycho-Social Services Can Offer Support During CAR T-Cell Therapy
Sally Werner, RN, BSN, MSHA, highlights the importance of using education, navigation programs, and caregiver support to help during CAR T-Cell Therapy treatment.
Comorbidities May Influence Teclistamab Induction Regimen Use in NDMM
The safety profile of teclistamab-based therapy in the MajesTEC-5 trial was expected based on the known compounds employed in each combination.
Considering Chemotherapy and Improving QOL in Mantle Cell Lymphoma Care
It may be critical to sequence BCL-2 inhibitors with BTK inhibitors for patients with mantle cell lymphoma in the relapsed/refractory setting.
Gemcitabine Intravesical System May Transform Bladder Cancer Treatment
Gary Steinberg, MD, discusses the clinical significance of the new FDA-approved gemcitabine intravesical system for BCG-unresponsive NMIBC.
Episode 14: Multidisciplinary Care Insights Across World GU 2025
Panelists and presenters attending World GU 2025 shared their perspectives on optimizing the management of prostate, kidney, and bladder cancers.